Zymeworks Q2 2023 net loss narrows 45% to $75.5M; zanidatamab Phase 2b data show 41.3% ORR

Zymeworks Inc.

2023-Q2 EPS reported -$1.13 revenue$42,580,000

Revenue surged to $42.6M (from $7.4M) on Jazz collaboration; net loss improved 45% YoY to $75.5M.
Cash and marketable securities $431.4M; runway expected through at least end-2026.
Zanidatamab Phase 2b BTC results: cORR 41.3%, median DOR 12.9 months, median PFS 5.5 months.
Next IND candidate ZW220 (NaPi2b-TOPO1i ADC) targeting NSCLC/ovarian cancer; IND filing expected 1H 2025.
Appointed Carlos E. Campoy to board; reiterated 2023 non-GAAP cash burn guidance $110M-$130M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.5

Zymeworks Inc. reported financial results for three and six months ended June 30, 2023.

Period: three and six months ended June 30, 2023
Result: reported results

Exact text from the filing

On August 10, 2023 , Zymeworks Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Zymeworks Inc. filing history →

Source: SEC EDGAR

accession 0001937653-23-000026

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.